Access Bio Inc (950130.KS) develops, manufactures and markets in vitro diagnostic tests for infectious diseases worldwide. The company offers rapid diagnostic tests including CareStart Malaria, CareStart Dengue Combo, CareStart G6PD RDT, CareStart Scrub Typhus IgM, CareStart COVID-19 Antigen and serology tests for SARS-CoV-2 detection; biosensors such as CareStart G6PD Biosensor and analyzers for measuring biological samples; molecular diagnostic products like CareStart HPV, CareStart CAH and PCR-based solutions for genome and proteome analysis. Founded in 2001 and headquartered in Somerset, New Jersey, Access Bio Inc operates manufacturing facilities in the US, South Korea and Ethiopia, serving international public health agencies, medical facilities and organizations focused on diseases including malaria, HIV, HPV, influenza, dengue and COVID-19. In recent developments, the company received KRW 9.49 billion in funding from Lion's Head Global Partners in support of its operations; expanded its COVID-19 portfolio with FDA Emergency Use Authorizations for point-of-care antigen, serology and molecular tests during the pandemic, including distribution of over 300 million home test kits; and built the largest rapid diagnostic test facility in the US post-COVID.